2.765  0.305 (12.4%)		01-30 11:49
Open: 2.65 High: 2.83 Volume: 1,143,013		Pre. Close: 2.46 Low: 2.54 Market Cap: 5(M)

Short term
Mid term
Targets	6-month :	4.15	1-year :	4.85
Resists	First :	3.55	Second :	4.15
Pivot price	2.66
Supports	First :	2.41	Second :	1.71
MAs	MA(5) :	2.44	MA(20) :	2.46
	MA(100) :	6.39	MA(250) :	11.35
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	37.7	D(3) :	34.5
RSI	RSI(14): 52.2
52-week	High :	55	Low :	1.71

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ GNPX ] has closed below upper band by 43.2%. Bollinger Bands are 86% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 51 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	3.12 - 3.14	3.14 - 3.16
Low:	2.06 - 2.08	2.08 - 2.1
Close:	2.43 - 2.46	2.46 - 2.49

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

Thu, 15 Jan 2026
Genprex, Inc. Stock (GNPX) Opinions on GPX-002 Diabetes Therapy Data - Quiver Quantitative

Sat, 10 Jan 2026
Genprex Regains Nasdaq Compliance but Faces Ongoing Monitoring - The Globe and Mail

Wed, 07 Jan 2026
Genprex Provides Clinical Update on Diabetes Gene Therapy Program - PR Newswire

Tue, 06 Jan 2026
Experimental gene therapy rejuvenates insulin cells in Type 2 diabetes tests - Stock Titan

Wed, 03 Dec 2025
Genprex, Inc. Stock (GNPX) Opinions on Recent Preclinical Data Release | GNPX Stock News - Quiver Quantitative

Fri, 21 Nov 2025
Genprex, Inc. Announces $75 Million Stock Offering - TradingView

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	-10 (M)
Shares Float	0 (M)
Held by Insiders	1.63e+006 (%)
Held by Institutions	2.27e+006 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	-1.633e+007
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	261.61
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-273.4 %
Return on Equity (ttm)	-1 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	-1 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	0.01
Price to Sales	0
Price to Cash Flow	0

Dividend	192580
Forward Dividend	188120
Dividend Yield	7002910%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.